

Yazi D Ke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3076573/publications.pdf>

Version: 2024-02-01

54
papers

4,544
citations

218662

26
h-index

189881

50
g-index

58
all docs

58
docs citations

58
times ranked

6577
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. <i>PLoS ONE</i> , 2022, 17, e0254296.	2.5	1
2	Recent progress in synthetic self-adjuvanting vaccine development. <i>Biomaterials Science</i> , 2022, 10, 4037-4057.	5.4	5
3	Loss of LAMP5 interneurons drives neuronal network dysfunction in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 144, 637-650.	7.7	15
4	Rapid initiation of cell cycle reentry processes protects neurons from amyloid- β^2 toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	19
5	ALS/FTD-causing mutation in cyclin F causes the dysregulation of SFPQ. <i>Human Molecular Genetics</i> , 2021, 30, 971-984.	2.9	16
6	Syntaxins 6 and 8 facilitate tau into secretory pathways. <i>Biochemical Journal</i> , 2021, 478, 1471-1484.	3.7	7
7	TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7781.	4.1	26
8	Overexpression of Tropomyosin Isoform Tpm3.1 Does Not Alter Synaptic Function in Hippocampal Neurons. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9303.	4.1	0
9	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. <i>Communications Medicine</i> , 2021, 1, .	4.2	14
10	The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors. <i>Frontiers in Chemistry</i> , 2021, 9, 781213.	3.6	2
11	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38 β . <i>Acta Neuropathologica</i> , 2020, 140, 279-294.	7.7	24
12	Neurodegeneration and Motor Deficits in the Absence of Astroglia upon Transgenic Mutant TDP-43 Expression in Mature Mice. <i>American Journal of Pathology</i> , 2020, 190, 1713-1722.	3.8	1
13	Contribution of endogenous antibodies to learning deficits and astrogliosis in human P301S mutant tau transgenic mice. <i>Scientific Reports</i> , 2020, 10, 13845.	3.3	2
14	Onset of motor deficits, but not their severity, is augmented by TREM2 reduction in P301S tau transgenic mice. <i>Alzheimer's and Dementia</i> , 2020, 16, e040610.	0.8	0
15	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. <i>Brain</i> , 2020, 143, 1889-1904.	7.6	12
16	K369I Tau Mice Demonstrate a Shift Towards Striatal Neuron Burst Firing and Goal-directed Behaviour. <i>Neuroscience</i> , 2020, 449, 46-62.	2.3	2
17	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	3.4	10
18	Developmental Expression of Mutant PFN1 in Motor Neurons Impacts Neuronal Growth and Motor Performance of Young and Adult Mice. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 231.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues. <i>British Journal of Pharmacology</i> , 2019, 176, 3649-3665.	5.4	22
20	Generation of a New Tau Knockout (tau ⁰ ex1) Line Using CRISPR/Cas9 Genome Editing in Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 571-578.	2.6	29
21	An N-terminal motif unique to primate tau enables differential protein-protein interactions. <i>Journal of Biological Chemistry</i> , 2018, 293, 3710-3719.	3.4	53
22	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. <i>American Journal of Pathology</i> , 2018, 188, 1447-1456.	3.8	8
23	Physiological changes in neurodegeneration – mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	10.1	72
24	Alzheimer's Disease and Frontotemporal Lobar Degeneration: Mouse Models. , 2018, , 187-219.		1
25	Peptide Nanofiber Substrates for Long-Term Culturing of Primary Neurons. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 25127-25134.	8.0	16
26	ALS/FTLD: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 177-196.	7.7	78
27	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	6.1	23
28	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. <i>Human Molecular Genetics</i> , 2017, 26, 1732-1746.	2.9	62
29	Tau exacerbates excitotoxic brain damage in an animal model of stroke. <i>Nature Communications</i> , 2017, 8, 473.	12.8	134
30	Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 48, 135-142.	3.1	63
31	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. <i>Neuroscience Letters</i> , 2016, 631, 24-29.	2.1	34
32	Site-specific phosphorylation of tau inhibits amyloid- β toxicity in Alzheimer's mice. <i>Science</i> , 2016, 354, 904-908.	12.6	241
33	No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. <i>PLoS ONE</i> , 2016, 11, e0163236.	2.5	35
34	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLTDP and ALS. <i>Acta Neuropathologica</i> , 2015, 130, 661-678.	7.7	61
35	A β -dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. <i>Nature Communications</i> , 2015, 6, 8836.	12.8	70
36	ERK inhibition with PD184161 mitigates brain damage in a mouse PD model of stroke. <i>Journal of Neural Transmission</i> , 2014, 121, 543-7.	2.8	20

#	ARTICLE	IF	CITATIONS
37	Alzheimer's Disease and Frontotemporal Lobar Degeneration: Mouse Models. , 2014, , 111-129.		0
38	Lessons from Tau-Deficient Mice. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	99
39	Tau-Mediated Nuclear Depletion and Cytoplasmic Accumulation of SFPQ in Alzheimer's and Pick's Disease. PLoS ONE, 2012, 7, e35678.	2.5	82
40	Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS ONE, 2011, 6, e26860.	2.5	142
41	Brief update on different roles of tau in neurodegeneration. IUBMB Life, 2011, 63, 495-502.	3.4	42
42	Cytoplasmic Accumulation and Aggregation of TDP-43 upon Proteasome Inhibition in Cultured Neurons. PLoS ONE, 2011, 6, e22850.	2.5	91
43	Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid- β . PLoS ONE, 2010, 5, e11070.	2.5	183
44	Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13888-13893.	7.1	237
45	Dissecting Toxicity of Tau and β -Amyloid. Neurodegenerative Diseases, 2010, 7, 10-12.	1.4	25
46	Dendritic Function of Tau Mediates Amyloid- β Toxicity in Alzheimer's Disease Mouse Models. Cell, 2010, 142, 387-397.	28.9	1,563
47	Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2009, 4, e7917.	2.5	161
48	Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 20909-20916.	3.4	139
49	Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. Journal of Neural Transmission, 2009, 116, 1243-1251.	2.8	35
50	Primary support cultures of hippocampal and substantia nigra neurons. Nature Protocols, 2009, 4, 78-85.	12.0	185
51	Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15997-16002.	7.1	201
52	Functional Genomics Dissects Pathomechanisms in Tauopathies: Mitosis Failure and Unfolded Protein Response. Neurodegenerative Diseases, 2008, 5, 179-181.	1.4	9
53	A Decade of Tau Transgenic Animal Models and Beyond. Brain Pathology, 2007, 17, 91-103.	4.1	145
54	Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation. International Journal of Developmental Neuroscience, 2006, 24, 437-443.	1.6	15